TalpheraTLPH
TLPH
About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Employees: 13
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
17% more funds holding
Funds holding: 29 [Q3] → 34 (+5) [Q4]
0.71% less ownership
Funds ownership: 24.58% [Q3] → 23.86% (-0.71%) [Q4]
40% less capital invested
Capital invested by funds: $3.58M [Q3] → $2.13M (-$1.45M) [Q4]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$6
1,163%
upside
Avg. target
$6
1,163%
upside
High target
$6
1,163%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target | 1,163%upside $6 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 5 articles about TLPH published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?
Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
2 weeks ago
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - CMO Conference Call Participants Thomas Yip - H.C. Wainwright Naz Rahman - Maxim Group Operator Welcome to the Talphera Fourth Quarter and Full Year 2024 Financial Results Conference call.
Neutral
PRNewsWire
2 weeks ago
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025 Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET SAN MATEO, Calif. , March 31, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.
Neutral
PRNewsWire
2 weeks ago
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the NEPHRO CRRT study should be completed by the end of 2025 Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules $4.925 million in gross proceeds at first closing with the potential to receive an additional $9.85 million across two $4.925 million tranches upon achieving certain patient enrollment milestones Cash and investments at December 31, 2024 of $8.9 million, together with the expected proceeds from the financing of up to $14.8 million should provide capital through targeted completion of the NEPHRO CRRT study by the end of 2025 SAN MATEO, Calif. , March 31, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously included in the study protocol.
Neutral
PRNewsWire
3 weeks ago
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m.
Neutral
PRNewsWire
3 months ago
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study SAN MATEO, Calif. , Jan. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), the agency has agreed to review a Prior Approval Supplement (PAS) requesting a reduction in the number of patients in the NEPHRO CRRT clinical study.
Neutral
Seeking Alpha
5 months ago
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Conference Call Participants James Molloy - Alliance Global Partners Thomas Yip - H.C. Wainwright Operator Welcome to the Talphera Third Quarter 2024 Financial Results Conference Call.
Neutral
PRNewsWire
5 months ago
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif. , Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.
Neutral
PRNewsWire
5 months ago
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
SAN MATEO, Calif. , Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m.
Neutral
PRNewsWire
6 months ago
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors.
Charts implemented using Lightweight Charts™